Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

Impact of Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03775031

Enrollment

Registered

2018-12-13

Start date

2019-12-01

Completion date

2021-07-01

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer

Brief summary

The purpose of this study is to evaluate the impact of fractional laser versus chemical peels on IGF-1 levels in skin.

Detailed description

This study is designed to assess the feasibility of using a fractional non ablative laser and chemical peels to wound skin, and thereby elicit a change in IGF-1. Our hypothesis is that fractional non ablative laser and a TCA chemical peel can induce similar effects as the fractional ablative laser at three months. In other words, our theory is that these approaches can stimulate the production of IGF-1 in older skin and restore UV damage repair and response mechanisms.

Interventions

DEVICEFractional Laser and Chemical Peel

Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

Randomized-Controlled (Subjects will serve as their own control)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male and female subjects \>55 years old * Fitzpatrick type I-II * Able to provide informed consent. * Cutaneous photodamage of 3 or above on the Larnier photodamage scale (see Appendix).

Exclusion criteria

* Prior laser or peel treatment in the area evaluated in the current study in the past year. * Currently taking immunosuppressant medications known to interfere wound healing or anti-inflammatory medications (such as NSAIDs, or steroids). * Subjects who have underlying diseases that could alter wound healing response (such as Diabetes). * Currently taking insulin. * History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study. * History of abnormal scarring such as Keloids. * History of vitiligo. * Allergy or sensitivity or allergy to topical anesthesia * Inability to use sunscreen. * History of smoking in the last 10 years * Scar or prior surgery in the area of treatment. * Use of isotretinoin in the prior 6 months * Subjects who have bleeding disorders or who are taking anticoagulants

Design outcomes

Primary

Measure	Time frame	Description
IGF-1 Levels	3 months	To quantify IGF-1 levels in skin

Countries

United States

Contacts

Primary ContactMolly Wanner, MD

mwanner@mgh.harvard.edu617-726-5066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026